Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.67 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30591972 | 1.00 | PTGDR2 (0.67) | PTGDR2LRRK2MAPTCYP2C9CYP2C19 | |
| SCHEMBL384896 | 0.89 | FOLH1 (0.68) | PTGDR2LRRK2L3MBTL1FOLH1LMNA | |
| SCHEMBL30361330 | 0.88 | MAOB (0.61) | PTGDR2LRRK2MAPTCYP2C9CYP2C19 | |
| SCHEMBL1106947 | 0.88 | MAOB (0.61) | PTGDR2LRRK2MAPTCYP2C9CYP2C19 | |
| SCHEMBL31053278 | 0.88 | PTGDR2 (0.59) | PTGDR2LRRK2MAPTCYP2C9CYP2C19 | |
| SCHEMBL28260622 | 0.86 | LRRK2 (0.59) | PTGDR2LRRK2SMN1; SMN2L3MBTL1FOLH1 | |
| SCHEMBL5431545 | 0.86 | LRRK2 (0.63) | LRRK2L3MBTL1FOLH1LMNAPOLB | |
| SCHEMBL23599368 | 0.85 | LRRK2 (0.55) | LRRK2FOLH1LMNAPOLBALDH1A1 | |
| SCHEMBL4723723 | 0.85 | LRRK2 (0.58) | LRRK2FOLH1LMNAPOLBKDM4E | |
| SCHEMBL5627324 | 0.85 | LRRK2 (0.56) | PTGDR2LRRK2FOLH1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150325-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS | LG CHEM, LTD. (KR) | 2024-05-09 | — | — | US | disclosed |
| EP-4273140-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | Lg Chem, Ltd. (KR) | 2023-11-08 | — | — | EP | disclosed |
| CN-116745279-A | Novel compounds as protein kinase inhibitors | 株式会社LG化学 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022169248-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | 주식회사 엘지화학 | 2022-08-11 | — | — | WO | disclosed |
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
| EP-3008052-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014201073-A9 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2014201073-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-11-06 | — | — | US | disclosed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150325-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS | MAP3K20, SBK3, MAPKAPK2 | PTGDR2 3299/4885LRRK2 174/4885MAPT 1526/4885 |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | PTGDR2 2329/4885LRRK2 4310/4885MAPT 4625/4885 |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | PTGDR2 1698/4885LRRK2 534/4885MAPT 1057/4885 |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | PTGDR2 1698/4885LRRK2 534/4885MAPT 1057/4885 |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | PTGDR2 2389/4885LRRK2 2944/4885MAPT 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.